NKNorihiko Kawamata

Norihiko Kawamata

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Norihiko Kawamata has a total of 55 co-authors. Here are the top co-authors by number of shared publications:

  • H. Phillip Koeffler

    Hematology/Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA

    9 shared publications
  • Seishi Ogawa

    University of Tokyo, Tokyo, Japan

    7 shared publications
  • Yasuhito Nannya

    Regeneration Medicine of Hematopoiesis, University of Tokyo, School of Medicine, Tokyo, Japan

    5 shared publications
  • Masashi Sanada

    2)Regeneration Medicine of Hematopoiesis, University of Tokyo, School of Medicine, Tokyo, Japan

    4 shared publications
  • Carl W. Miller

    1)Hematology/Oncology, Cedars-Sinai Medical Center/ UCLA School of Medicine, Los Angeles, CA

    3 shared publications
  • Azadeh Dashti

    Hematology/Oncology, Cedars-Sinai Medical Center/David Geffen School of Medicine at UCLA, Los Angeles, CA

    2 shared publications

Latest Publications

  • Open Access

    Genetic differences between Asian and Caucasian chronic lymphocytic leukemia

    by Norihiko Kawamata, Chimene Moreilhon, Takayuki Saitoh, Masamitsu Karasawa, Brian K. Bernstein, Aiko Sato-Otsubo, Seishi Ogawa, Sophie Raynaud, H. Phillip Koeffler

    Chronic lymphocytic leukemia (CLL) is a common hematological malignancy in Western countries. However, this disease is very rare in Asian countries. It is not clear whether the mechanisms of development of CLL in Caucasians and Asians are the same. We compared genetic abnormalities in Asian and Caucasian CLL using 250k GeneChip arrays. Both Asian and Caucasian CLL had four common genetic abnormalities: deletion of 13q14.3, trisomy 12, abnormalities of ATM (11q) and abnormalities of 17p. Interestingly, trisomy 12 and deletion of 13q14.3 were mutually exclusive in both groups. We also found that deletions of miR 34b/34c (11q), caspase 1/4/5 (11q), Rb1 (13q) and DLC1 (8p) are common in both ethnic groups. Asian CLL more frequently had gain of 3q and 18q. These suggest that classic genomic changes in the Asian and Caucasina CLL are same. Further, we found amplification of IRF4 and deletion of the SP140/SP100 genes; these genes have been reported as CLL-associated genes by previous genome-wide-association study. We have found classic genomic abnormalities in Asian CLL as well as novel genomic alteration in CLL.


  • Double minute chromosomes containing MYB gene and NUP214-ABL1 fusion gene in T-cell leukemia detected by single nucleotide polymorphism DNA microarray and fluorescence in situ hybridization

    by Norihiko Kawamata, Ling Zhang, Seishi Ogawa, Yasuhito Nannya, Azadeh Dashti, Daning Lu, Stephen Lim, Rhona Schreck, H.PHillip Koeffler


  • Genetic profiling of myeloproliferative disorders by single-nucleotide polymorphism oligonucleotide microarray

    by Norihiko Kawamata, Seishi Ogawa, Go Yamamoto, Soren Lehmann, Ross L. Levine, Yana Pikman, Yasuhito Nannya, Masashi Sanada, Carl W. Miller, D. Gary Gilliland, et al.


  • Cloning of genes involved in chromosomal translocations by high-resolution single nucleotide polymorphism genomic microarray

    by Norihiko Kawamata, Seishi Ogawa, Martin Zimmermann, Birte Niebuhr, Carol Stocking, Masashi Sanada, Kari Hemminki, Go Yamatomo, Yasuhito Nannya, Rolf Koehler, et al.

    High-resolution single nucleotide polymorphism genomic microarray (SNP-chip) is a useful tool to define gene dosage levels over the whole genome, allowing precise detection of deletions and duplications/amplifications of chromosomes in cancer cells. We found that this new technology can also identify breakpoints of chromosomes involved in unbalanced translocations, leading to identification of fusion genes. Using this technique, we found that thePAX5gene was rearranged to a variety of partner genes includingETV6,FOXP1,AUTS2, andC20orf112in pediatric acute lymphoblastic leukemia (ALL). The 3′ end of thePAX5gene was replaced by the partner gene. The PAX5 fusion products bound to PAX5 recognition sequences as strongly as wild-type PAX5 and suppressed its transcriptional activity in a dominant-negative fashion. In human B cell leukemia cells, binding of wild-type PAX5 to a regulatory region ofBLK, one of the direct downstream target genes of PAX5, was diminished by expression of the PAX5-fusion protein, leading to repression ofBLK. Expression of PAX5-fusion genes in murine bone marrow cells blocked development of mature B cells. PAX5-fusion proteins may contribute to leukemogenesis by blocking differentiation of hematopoietic cells into mature B cells. SNP-chip is a powerful tool to identify fusion genes in human cancers.


  • Chronic phase of ETV6‐ABL1 positive CML responds to imatinib

    by Norihiko Kawamata, Azadeh Dashti, Daning Lu, Becky Miller, H. Phillip Koeffler, Rhona Schreck, Stephen Moore, Seishi Ogawa


  • Open Access

    Molecular allelokaryotyping of early‐stage, untreated chronic lymphocytic leukemia

    by Sören Lehmann, Seishi Ogawa, Sophie D. Raynaud, Masashi Sanada, Yasuhito Nannya, Michel Ticchioni, Christian Bastard, Norihiko Kawamata, H. Phillip Koeffler

    BACKGROUND.: To the authors' knowledge, genetic abnormalities in early‐stage chronic lymphocytic leukemia (CLL) have not been examined fully. Single nucleotide polymorphism (SNP) genomic array (SNP‐chip) is a new tool that can detect copy number changes and uniparental disomy (UPD) over the entire genome with very high resolution.METHODS.: The authors performed SNP‐chip analysis on 56 samples from patients with early‐stage, untreated CLL. To validate the SNP‐chip data, fluorescence in situ hybridization (FISH) analysis was performed at selected sites. Expression levels of ZAP‐70 and the mutational status of immunoglobulin heavy‐chain gene also were examined.RESULTS.: SNP‐chip analysis easily detected nearly all changes that were identified by FISH, including trisomy 12, deletion of TP53 (17p13), deletion of ATM (11q22), and deletion of 13q14. Only 10 of 56 CLL samples (18%) had no genomic abnormalities. Excluding the 4 common abnormalities mentioned above, 25 CLL samples (45%) had a total of 45 copy number changes detected by SNP‐chip analysis. Four samples had 6q deletion at 6q21 that involved the AIM1 gene. UPD was detected in 4 samples; 2 samples involved whole chromosome 13 resulting in homozygous deletion of micro‐RNA‐15a (miR‐15a)/miR‐16‐1. CLL samples with deletion of 13q14 and trisomy 12 were mutually exclusive.CONCLUSIONS.: Genetic abnormalities, including whole chromosome 13 UPD, are very common events in early‐stage CLL. SNP‐chip analysis can detect small genetic abnormalities in CLL and may be able to support or even supplant FISH and cytogenetics. Cancer 2008. © 2008 American Cancer Society.


  • Open Access

    Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray

    by Norihiko Kawamata, Seishi Ogawa, Martin Zimmermann, Motohiro Kato, Masashi Sanada, Kari Hemminki, Go Yamatomo, Yasuhito Nannya, Rolf Koehler, Thomas Flohr, et al.

    Pediatric acute lymphoblastic leukemia (ALL) is a malignant disease resulting from accumulation of genetic alterations. A robust technology, single nucleotide polymorphism oligonucleotide genomic microarray (SNP-chip) in concert with bioinformatics offers the opportunity to discover the genetic lesions associated with ALL. We examined 399 pediatric ALL samples and their matched remission marrows at 50 000/250 000 SNP sites using an SNP-chip platform. Correlations between genetic abnormalities and clinical features were examined. Three common genetic alterations were found: deletion of ETV6, deletion of p16INK4A, and hyperdiploidy, as well as a number of novel recurrent genetic alterations. Uniparental disomy (UPD) was a frequent event, especially affecting chromosome 9. A cohort of children with hyperdiploid ALL without gain of chromosomes 17 and 18 had a poor prognosis. Molecular allelokaryotyping is a robust tool to define small genetic abnormalities including UPD, which is usually overlooked by standard methods. This technique was able to detect subgroups with a poor prognosis based on their genetic status.


  • Open Access

    Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells

    by Norihiko Kawamata, John Chen, H. Phillip Koeffler

    Mantle cell lymphoma (MCL) has a chromosomal translocation resulting in the expression of the cyclin D1 gene driven by the powerful enhancer of the immunoglobulin heavy chain gene, leading to uncontrolled, overexpressed cyclin D1 protein. We showed that suberoylanilide hydroxamic acid (SAHA; vorinostat), one of the histone deacetylase inhibitors derived from hydroxamic acid, caused a dramatic decrease (90%) in protein levels of cyclin D1 after 8-hour exposure to SAHA (5 μM) in MCL lines (SP49, SP53, Jeko1). mRNA levels and protein stability of cyclin D1 were minimally affected by SAHA over 8 hours. In contrast, metabolic labeling assays showed that SAHA decreased incorporation of [35S]methionine into cyclin D1 protein. The drug also decreased levels of phosphorylated Akt, mammalian target of Rapamycin (mTOR), and eukaryotic translation initiation factor 4E binding protein (eIF4E-BP) and lowered the cap site binding activity of eIF4E in the MCL cells. In vitro phosphatidyl inositol (PI) kinase assay demonstrated that SAHA directly inhibited kinase activity of PI 3′ kinase. Taken together, SAHA caused a rapid decrease of cyclin D1 in MCL by blocking the translation of cyclin D1 by inhibiting the phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR/eIF4E-BP pathway, probably by PI3K inhibition.


  • Open Access

    2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth

    by Noriyuki Takai, Anjali Jain, Norihiko Kawamata, Laura M. Popoviciu, Jonathan W. Said, Sadie Whittaker, Isao Miyakawa, David B. Agus, H. Phillip Koeffler

    BACKGROUND: Human epidermal growth factor receptor 2 (HER2) is overexpressed in 25–30% of ovarian carcinoma cases and a correlation between increased HER2 expression and decreased survival has been demonstrated. HER2 is a ligand‐less member of the HER family that functions as the preferred coreceptor for epidermal growth factor receptor (EGFR), HER3, and HER4.METHODS: An approach was developed to target HER2's role as a coreceptor using a monoclonal antibody, 2C4, which sterically hinders HER2's recruitment into a functional HER complex.RESULTS: HER2 was robustly expressed in all eight ovarian carcinoma cell lines; expression of EGFR and HER3 was variable. Even though four of the eight cell lines responded to EGF, 2C4 antibody moderately inhibited in vitro proliferation of only two cell lines (OVCA433 and SK‐OV‐3). Furthermore, ligand‐stimulated p‐MAPK expression was inhibited by 2C4 only in these two cell lines after exposure to EGF. Immunoprecipitation and eTag analysis revealed that OVCA433 expressed heterodimers of EGFR/HER2, and these heterodimers were disrupted after treatment with 2C4, whereas OVCA432 cells did not have these heterodimers. In murine xenograft experiments, the in vivo growth of OVCA433, but not of OVCA432, ovarian carcinoma cells was significantly inhibited by 2C4 treatment of the mice.CONCLUSION: 2C4 is able to disrupt the HER signaling pathway and inhibit the in vitro and in vivo growth of ovarian carcinoma cell lines. The response appears limited to lines in which HER2 heterodimers were able to transduce proliferative signals. Our findings suggest a strong rationale to conduct clinical trials of 2C4 in a subset of patients with ovarian tumors. Cancer 2005. © 2005 American Cancer Society.


  • Mxi1 isoforms are expressed in hematological cell lines and normal bone marrow

    by Norihiko Kawamata, Kei-Ji Sugimoto, Sakura Sakajiri, Kazuo Oshimi, H. Phillip Koeffler